greater efficacy was demonstrated for once per day upadacitinib 15 mg and 30 mg versus placebo for clinical manifestations of psoriatic arthritis including musculoskeletal symptoms (peripheral ...

In addition to inhibiting radiographic progression in patients with PsA, adalimumab resulted in sustained improvement of joint and skin-related symptoms throughout 2 years of treatment. Improvements ...

Spondyloarthritis (SpA), if not diagnosed and treated early, often leads to significant morbidity. Unfortunately, diagnosis and implementation of therapy are frequently delayed, in many cases by ...